Momenta Pharmaceuticals (MNTA) Tops Q3 EPS by 2c; Revs Light
More News related to MNTA
- FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
- Momenta Pharmaceuticals (MNTA) Dec volatility at 89, March at 121 into FDA
- Oppenheimer Upgrades Momenta Pharmaceuticals (MNTA) to Outperform
- Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
- Canaccord Adams Initiates Coverage on Momenta Pharmaceuticals (MNTA) with a Buy
More News related to Earnings
- Top 10 News Items 11/23-11/27: Dubai Debt Fallout; Gold; GDP Revised Lower; Diedrich Coffee Bidding War
- Trading Radar for 11/30: Inergy Holdings (NRGP), Golar (GLNG), Omnivision (OVTI), Knightsbridge (VLCCF) Report
- Notable Mergers and Acquisitions of the Day for 11/27: F, S/IPCS, STAR/CSCO, HRAY
- Notable Analyst Rating Changes 11/27: TIF, QLTI Upgraded; FSNM, RGFC Downgraded
- Notable ETF Movers *Special Dubai World Edition* 11/27: UUP Higher; GAF, EEM, FXI, XLF Lower
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) reports a Q3 loss of $0.38, 2 cents better than estimates. Revenues were $4.0 million vs. $4.74 million consensus.
At September 30, 2009, the Company had cash, cash equivalents, and marketable securities of $107.3 million, compared with $108.5 million at December 31, 2008.
[SM]
Related Categories
EarningsStocks Mentioned
-0.40Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
